The MASP-2 inhibitor narsoplimab was associated with rapid and sustained reduction of circulating endothelial cell counts and serum IL-6, IL-8, CRP, and lactate dehydrogenase (LDH) in six patients with COVID-19 on mechanical ventilation, correlating with clinical improvement [93]. This evidence concerns the gene CRP and COVID-19.